Characteristics of converters
| No. | Sex/age | Diagnosis | TB risk factors (other than age) | BCG | Steroids | DMARDs | Anti-TNF | TST | T-SPOT.TB | QFT-GIT | INH |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/41 | PsA | No | No | No | No | ETN | 10 mm | No | ||
| 2 | M/55 | PsA | No | No | No | No | ETN | 10 mm | No | ||
| 3 | M/42 | PsA | No | No | No | No | ADA | 28.02 IU/mL | No | ||
| 4 | F/14 | PG | No | Yes | Yes (5 mg/day) | No | ADA | >100 spots (panel A) | No | ||
| 5 | F/44 | AS | No | No | No | No | INFL | 11 mm | Yes | ||
| 6 | F/63 | RA | No | Yes | No | LEF | ETN | >100 spots (panels A and B) | No | ||
| 7 | M/25 | PsA | No | No | No | MTX | ADA | 30.19 IU/mL | Yes | ||
| 8 | M/26 | PsA | No | No | No | MTX | ETN | 0.6 IU/mL | Yes | ||
| 9 | F/51 | AS | No | No | No | No | ADA | 8 spots (panel A) | Yes | ||
| 10 | F/60 | RA | No | Yes | Yes (5 mg/day) | MTX | ADA | 13 mm | Yes | ||
| 11 | F/67 | RA | No | No | Yes (5 mg/day) | MTX | CTZ | >100 spots (panel A) | No | ||
| 12 | F/54 | RA | Yes | No | Yes (5 mg/day) | LEF | ADA | 15 mm | No | ||
| 13 | M/37 | AS | No | No | No | No | ADA | 8 mm | Yes | ||
| 14 | M/68 | RA | No | No | Yes (5 mg/day) | MTX | ETN | 11 mm | No | ||
| 15 | F/73 | RA | Yes | Yes | Yes (5 mg/day) | MTX | ADA | 15 spots (panel B) | No | ||
| 16 | F/72 | RA | No | No | No | CsA | ETN | 0.48 IU/mL | Yes | ||
| 17 | F/74 | RA | No | No | Yes (5 mg/day) | MTX | CTZ | 8 spots (panel A) | No | ||
| 18 | F/73 | RA | No | No | Yes (5 mg/day) | MTX | GOL | 10 mm | No | ||
| 19 | F/39 | PsA | Yes | No | No | MTX | GOL | 12 spots (panel A) | Yes | ||
| 20 | M/32 | AOSD | Yes | Yes | Yes (10 mg/day) | MTX | ETN | 15 mm | 0.44 IU/mL | No |
The detailed characteristics of patients who converted at least one screening assay (IGRA or TST) during the 1 year of anti-TNF therapy are given. The individual results of the TST, T-SPOT.TB and QFT-GIT are also shown.
ADA, adalimumab; AOSD, adult-onset Still's disease; AS, ankylosing spondylitis; CsA, cyclosporine; CTZ, certolizumab pegol; DMARDs, disease modifying anti-rheumatic drugs; ETN, etanercept; F, female; GOL, golimumab; HCQ, hydroxychloroquine; IGRA, interferon-γ gamma release assay; INFL, infliximab; INH, isoniazid; LEF, leflunomide; M, male; MTX, methotrexate; PG, pyoderma gangrenosum; PsA, psoriatic arthritis; QFT-GIT, QuantiFERON-TB Gold In Tube; RA, rheumatoid arthritis; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test.